Search the Newsreel

Xenon Pharmaceuticals Independent Director Steven Gannon Sells 84% Of Holding

Theravance Biopharma Deal Faces Investor Probe

Halper Sadeh LLC is investigating the proposed acquisition of Theravance Biopharma (NASDAQ: TBPH) by Zymeworks Inc. for $17 per share in cash plus a contingent value right. The investigation aims to determine if Theravance shareholders are receiving a fair price and if the company's …

Technical Reactions to AVBP Trends in Macro Strategies

This article provides a technical analysis of Arrivent Biopharma Inc. (NASDAQ: AVBP) trends, highlighting neutral near and mid-term readings but a potentially strong long-term positive bias. It details institutional trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The …

Summit Global Investments Acquires Shares of 7,182 Vertex Pharmaceuticals Incorporated $VRTX

Summit Global Investments purchased 7,182 shares of Vertex Pharmaceuticals (NASDAQ:VRTX) in the second quarter, valued at approximately $3.57 million. Other hedge funds also adjusted their holdings, with institutional investors now owning 90.96% of the stock. Analysts currently have a "Moderate Buy" rating for VRTX …

7,506 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Summit Global Investments

Summit Global Investments acquired 7,506 shares of Regeneron Pharmaceuticals (NASDAQ:REGN) valued at $4.68 million during the second quarter. Regeneron reported strong quarterly results, beating analyst estimates with $14.29 EPS and $4.29 billion in revenue, representing a 16.7% year-over-year increase. Despite a "Moderate Buy" consensus …

Rhythm Pharmaceuticals(RYTM.US) Officer Sells US$8.9 Million in Common Stock

An officer at Rhythm Pharmaceuticals (RYTM.US) recently sold a substantial amount of common stock, totaling US$8.9 million. This transaction indicates a significant insider sale for the company.

CarMax, Inc. $KMX Shares Sold by Qsemble Capital Management LP

Qsemble Capital Management LP significantly reduced its stake in CarMax, Inc. (KMX) by 81% in the second quarter, selling over 130,000 shares. Despite this, CarMax reported strong quarterly revenue of $8.01 billion and exceeded EPS estimates, though its EPS was down year-over-year. Analyst sentiment …

TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Theravance Biopharma, Inc. (NASDAQ: TBPH) to Zymeworks Inc. for $17.00 per share. The investigation focuses on whether Theravance's board failed to secure the best possible price, conducted a fair sales process, …

Walleye Capital LLC Buys Shares of 106,112 ANI Pharmaceuticals, Inc. $ANIP

Walleye Capital LLC has acquired a new position in ANI Pharmaceuticals, purchasing 106,112 shares valued at approximately $8.8 million, indicating growing institutional interest as hedge funds and other investors collectively own 76.05% of the company. ANI Pharmaceuticals recently surpassed quarterly earnings expectations, reporting adjusted …

Spyglass Pharma (NASDAQ:SGP) Upgraded to "Moderate Buy" at Raymond James Financial

Trifecta Capital Advisors LLC Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX

Trifecta Capital Advisors LLC has acquired a new position in Vertex Pharmaceuticals (NASDAQ:VRTX), purchasing 16,745 shares valued at approximately $8.318 million, making it their 27th largest holding. Other institutional investors like Capital Research Global Investors and State Street Corp also increased their stakes. This …

Oppenheimer Asset Management Inc. Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX

Oppenheimer Asset Management Inc. has acquired a new stake of 17,931 shares in Vertex Pharmaceuticals (NASDAQ:VRTX), valued at approximately $8.91 million during the second quarter. This new investment comes as other institutional investors have also adjusted their holdings in VRTX. Vertex Pharmaceuticals reported earnings …

ProVise Management Group LLC Has $282,000 Position in CarMax, Inc. $KMX

ProVise Management Group LLC significantly reduced its stake in CarMax, Inc. (NYSE:KMX) by 95.2% in the second quarter, now holding 5,340 shares valued at $282,000. Despite this, other hedge funds increased their positions in CarMax, with notable acquisitions by SRS Investment Management LLC and …

86,249 Shares in Eton Pharmaceuticals, Inc. $ETON Acquired by Walleye Capital LLC

Walleye Capital LLC has acquired 86,249 shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) during the second quarter, valued at approximately $3.12 million, representing a 0.31% stake in the company. This acquisition comes as Eton Pharmaceuticals reported strong quarterly results, exceeding revenue and EPS expectations, and …

Quantinno Capital Management LP Buys 24,878 Shares of Crinetics Pharmaceuticals, Inc. $CRNX

Quantinno Capital Management LP significantly increased its stake in Crinetics Pharmaceuticals, Inc. (CRNX) by 280.9% in Q1, acquiring an additional 24,878 shares to reach a total of 33,734 shares valued at $1.225 million. This comes as Crinetics Pharmaceuticals reported strong Q1 revenues of $25.12 …

California State Teachers Retirement System Grows Stock Holdings in Urogen Pharma $URGN

The California State Teachers Retirement System significantly increased its holdings in Urogen Pharma (NASDAQ:URGN) by 1,605.5% in the first quarter, now owning 38,750 shares valued at $697,000. Institutional investors collectively hold 91.29% of the company, which has an average analyst rating of "Moderate Buy" …

How Investors May Respond To ANI Pharmaceuticals (ANIP) Record Q2 Results And Reaffirmed 2026 Revenue Guidance

Crinetics Pharmaceuticals (CRNX) Reports Q2 2026 Results, Is The Stock About Right?

ARS Pharmaceuticals (SPRY) Stock Faces Margin Squeeze As Losses Deepen

Walleye Capital LLC Invests $4.84 Million in Xeris Biopharma Holdings, Inc. $XERS

Walleye Capital LLC has invested $4.84 million in Xeris Biopharma Holdings, Inc. by acquiring 611,296 shares in the second quarter, representing 0.35% of the company. Institutional investors collectively own 42.75% of Xeris. Despite reporting higher-than-expected revenue of $92.1 million, the company posted an adjusted …

Walleye Capital LLC Buys New Position in Xenon Pharmaceuticals Inc. $XENE

Walleye Capital LLC has acquired a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE), purchasing 76,955 shares valued at approximately $4.65 million. This move is amidst positive analyst sentiment with a "Buy" rating and a $77.13 average price target, despite recent insider stock sales totaling …

Amylyx Pharmaceuticals (AMLX) Stock Trades At A Premium After Avexitide Trial Progress

Amylyx Pharmaceuticals (AMLX) stock has seen a 170.4% return over the past year, but its valuation metrics suggest it is trading at a premium. The progress of the avexitide trial, including its completed pivotal trial and potential commercial launch, supports future cash flow expectations, …

Redcare Pharmacy Aktie • A2AR94 • NL0012044747

Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands

Madrigal Pharmaceuticals' drug Rezdiffra achieved a $1.3 billion trailing-12-month revenue run rate in Q2 2026, with revenue up 71% year-over-year and over 49,000 active patients. The company is expanding its MASH pipeline to 10 assets, primarily for combination with Rezdiffra, targeting weight loss, liver-fat …

Wedge Capital Management L L P NC Buys Shares of 128,845 Theravance Biopharma, Inc. $TBPH

Wedge Capital Management L L P NC recently acquired 128,845 shares of Theravance Biopharma (NASDAQ:TBPH) worth approximately $2.19 million, now owning about 0.25% of the company. Institutional investors hold 99.10% of TBPH, despite the company reporting an adjusted loss and missing revenue expectations in …

Milestone’s FDA Win Now Faces A Tougher Test: Sales

Milestone Pharmaceuticals (NASDAQ: MIST) recently gained FDA approval for its lead product, CARDAMYST™ (etripamil) nasal spray, for PSVT. However, the company now faces the challenge of commercializing the product, with early sales and market sentiment being mixed. The success of CARDAMYST depends heavily on …

How Securities Lawsuits Over Trial Disclosures Will Impact Regeneron Pharmaceuticals’ (REGN) Pipeline-Driven Investment Story

Regeneron Pharmaceuticals is facing securities class action lawsuits concerning alleged misleading statements about its Phase III Fianlimab-Libtayo trial. These lawsuits, focusing on disclosure practices regarding trial delays and failure, could influence investor perception of Regeneron's pipeline-driven strategy, especially as the company advances new programs …

Empowered Funds LLC Buys 119,202 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Empowered Funds LLC significantly increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 661.6% in the first quarter, adding 119,202 shares to reach a total of 137,220 shares valued at $8.6 million. This move is part of a broader trend of institutional investment, with …

IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Rating of "Moderate Buy" from Analysts

NRx Pharmaceuticals (NASDAQ:NRXP) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $34.50. Despite this, the company recently missed its quarterly earnings and revenue estimates. Hedge funds and institutional investors hold 4.27% of the stock.

Bank of America Corp DE Boosts Stake in Kiniksa Pharmaceuticals International, plc $KNSA

Connect Biopharma (NASDAQ:CNTB) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen has upgraded Connect Biopharma (NASDAQ:CNTB) from a "sell" to a "hold" rating, though the broader analyst consensus remains a "Moderate Buy" with an average price target of $7.43. The company recently reported a quarterly loss of $0.27 per share, outperforming expectations, …

Vertex (VRTX) Stock Looks Above Fair Value On Earnings Yet About Right Overall

Vertex Pharmaceuticals (VRTX) has seen strong multi-year performance, with a 158.2% return over the past five years, but its current valuation suggests it's neither a clear bargain nor obviously overvalued. The stock trades at 29.1x earnings, slightly above Simply Wall St's fair P/E estimate …

ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data

How (HASI) Movements Inform Risk Allocation Models

This article analyzes Hannon Armstrong Sustainable Infrastructure Capital Inc. (NASDAQ: HASI) using AI models, indicating strong sentiment across all horizons and an exceptional 25.3:1 risk-reward setup. It outlines specific institutional trading strategies (Position Trading, Momentum Breakout, and Risk Hedging) with entry, target, and stop-loss …

Sprouts Farmers Market, Inc. (NASDAQ:SFM) Given Consensus Recommendation of "Hold" by Brokerages

Brokerages have given Sprouts Farmers Market (NASDAQ:SFM) a consensus "Hold" recommendation, with an average 12-month price target of $91.58 among 14 analysts. While the company recently exceeded earnings and revenue expectations, analysts noted softer comparable sales and margin pressure, leading to some reduced near-term …